PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10921025-2 1998 METHODS: Apoptosis of in vitro cultured K562 cells was observed after exposure to synthetic 18-mer antisense oligodeoxynucleotide complementary to the bcr-abl junction (b3a2). Oligodeoxyribonucleotides 109-129 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 151-158 10565030-0 2000 Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides. Oligodeoxyribonucleotides 81-102 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-19 10414920-1 1999 Antisense oligodeoxyribonucleotides (ODN) targeted against the breakpoint in BCR-ABL mRNA will specifically decrease BCR-ABL mRNA, provided cells are first permeabilised with streptolysin-O (SL-O). Oligodeoxyribonucleotides 10-35 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 77-84 10414920-1 1999 Antisense oligodeoxyribonucleotides (ODN) targeted against the breakpoint in BCR-ABL mRNA will specifically decrease BCR-ABL mRNA, provided cells are first permeabilised with streptolysin-O (SL-O). Oligodeoxyribonucleotides 10-35 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 117-124 15730714-1 2004 OBJECTIVES: To investigate targeted blockage of BCR/ABL oncoprotein mediated cell transformation by STAT5 decoy oligodeoxynucleotide (ODN), its effect on the growth and proliferation inhibition of K562 cells and the related molecular mechanisms. Oligodeoxyribonucleotides 112-132 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 48-55 9305594-1 1997 Antisense oligodeoxyribonucleotides (ODN) have been shown to produce a sequence-specific cleavage of BCR-ABL mRNA. Oligodeoxyribonucleotides 10-35 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 101-108 9616172-1 1998 The hybrid gene BCR-ABL that typifies chronic myeloid leukemia (CML) represents an attractive target for therapy with antisense oligodeoxyribonucleotides (ODN). Oligodeoxyribonucleotides 128-153 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 16-23 9616172-1 1998 The hybrid gene BCR-ABL that typifies chronic myeloid leukemia (CML) represents an attractive target for therapy with antisense oligodeoxyribonucleotides (ODN). Oligodeoxyribonucleotides 155-158 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 16-23 9558370-0 1998 BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase. Oligodeoxyribonucleotides 18-38 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 9558370-1 1998 BCR-ABL antisense oligodeoxynucleotides (ODN) have provided evidence of antileukemia effect when tested in vitro against Philadelphia-positive (Ph-pos) cells and in vivo when injected into leukemic mice. Oligodeoxyribonucleotides 18-39 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 9558370-1 1998 BCR-ABL antisense oligodeoxynucleotides (ODN) have provided evidence of antileukemia effect when tested in vitro against Philadelphia-positive (Ph-pos) cells and in vivo when injected into leukemic mice. Oligodeoxyribonucleotides 41-44 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 0-7 9558400-0 1998 Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors. Oligodeoxyribonucleotides 48-69 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 14-21 7606003-0 1995 Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA. Oligodeoxyribonucleotides 26-46 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 71-78 8907275-1 1996 We have previously demonstrated that liposome-incorporated methylphosphonate antisense oligodeoxynucleotides (oligos) specific for BCR-ABL can selectively inhibit the expression of p210Bcr-Abl protein and the proliferation of chronic myelogenous leukemia cells in vitro. Oligodeoxyribonucleotides 87-108 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 131-138 7579358-0 1995 BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Oligodeoxyribonucleotides 18-43 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 4-7 7579442-0 1995 Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Oligodeoxyribonucleotides 0-21 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 35-40 8597610-1 1996 Uptake and biochemical and biological effects of antisense oligodeoxynucleotides (ODN) specific for c-abl and bcr genes were studied in normal immature myeloid cells. Oligodeoxyribonucleotides 59-80 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 100-105 8597610-1 1996 Uptake and biochemical and biological effects of antisense oligodeoxynucleotides (ODN) specific for c-abl and bcr genes were studied in normal immature myeloid cells. Oligodeoxyribonucleotides 82-85 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 100-105 8535209-3 1995 Short oligodeoxynucleotide (ODN) sequences complementary (or antisense) to the bcr-abl junction may have potential as leukaemia-specific therapy. Oligodeoxyribonucleotides 6-26 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 79-86 7606003-1 1995 Antisense oligodeoxynucleotides targeted to bcr-abl are potential ex vivo purging agents for use with autologous bone marrow transplantation in the treatment of chronic myeloid leukemia (CML). Oligodeoxyribonucleotides 10-31 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 44-51 1857987-0 1991 Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Oligodeoxyribonucleotides 73-94 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 55-62 7701917-2 1994 Specific inhibition of the BCR-ABL gene expression with antisense oligodeoxynucleotides has been shown to have profound effects on cell growth in vitro. Oligodeoxyribonucleotides 66-87 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 27-34 8118022-3 1994 Antisense oligodeoxynucleotides corresponding to the translation start of bcr downregulate bcr-abl protein in these cells and render them susceptible to induction of apoptosis by chemotherapeutic agents or serum deprivation. Oligodeoxyribonucleotides 10-31 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 91-98 8026602-1 1994 Synthetic oligodeoxynucleotides (antisenses) complementary to bcr/abl breakpoint junction transcript on Philadelphia chromosome, or c-myb protooncogene inhibit partially the proliferation of Philadelphia positive leukemic cells (antisenses against bcr/abl and c-myb) and other tumor cells (antisenses against c-myb). Oligodeoxyribonucleotides 10-31 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 62-69 8026602-1 1994 Synthetic oligodeoxynucleotides (antisenses) complementary to bcr/abl breakpoint junction transcript on Philadelphia chromosome, or c-myb protooncogene inhibit partially the proliferation of Philadelphia positive leukemic cells (antisenses against bcr/abl and c-myb) and other tumor cells (antisenses against c-myb). Oligodeoxyribonucleotides 10-31 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 248-255 2672339-4 1989 The c-abl antisense oligodeoxynucleotides inhibited myeloid, but not erythroid, colony formation. Oligodeoxyribonucleotides 20-41 ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens 4-9